24.02
-0.33 (-1.36%)
| Penutupan Terdahulu | 24.35 |
| Buka | 24.21 |
| Jumlah Dagangan | 438,442 |
| Purata Dagangan (3B) | 553,595 |
| Modal Pasaran | 1,436,336,000 |
| Harga / Jualan (P/S) | 650.22 |
| Harga / Buku (P/B) | 7.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| EPS Cair (TTM) | -37.90 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.06% |
| Nisbah Semasa (MRQ) | 7.32 |
| Aliran Tunai Operasi (OCF TTM) | -151.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.86 M |
| Pulangan Atas Aset (ROA TTM) | -38.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -91.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Spyre Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -4.0 |
| Purata | 0.63 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.80% |
| % Dimiliki oleh Institusi | 88.77% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 65.00 (Baird, 170.61%) | Beli |
| 65.00 (Guggenheim, 170.61%) | Beli | |
| Median | 65.00 (170.61%) | |
| Purata | 65.00 (170.61%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 33.90 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 13 Nov 2024 | 65.00 (170.61%) | Beli | 32.98 |
| Guggenheim | 25 Oct 2024 | 65.00 (170.61%) | Beli | 34.81 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |